

# Joseph M Connors

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3047392/joseph-m-connors-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

449  
papers

55,764  
citations

95  
h-index

234  
g-index

465  
ext. papers

64,104  
ext. citations

5.7  
avg, IF

6.85  
L-index

#	Paper	IF	Citations
449	Circos: an information aesthetic for comparative genomics. <i>Genome Research</i> , <b>2009</b> , 19, 1639-45	9.7	6014
448	Revised response criteria for malignant lymphoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 579-86	2.2	3483
447	The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1937-47	59.2	2971
446	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , <b>2004</b> , 103, 275-82	2.2	2955
445	Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 1244	2.2	2910
444	Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. <i>Nature Genetics</i> , <b>2010</b> , 42, 181-5	36.3	1273
443	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. <i>Nature</i> , <b>2011</b> , 476, 298-303	50.4	1180
442	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , <b>2010</b> , 463, 88-92	50.4	1149
441	Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 2159-69	59.2	1141
440	Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2183-9	2.2	1091
439	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , <b>2011</b> , 470, 115-9	50.4	1068
438	Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 875-85	59.2	961
437	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , <b>2007</b> , 109, 1857-61	2.2	955
436	Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. <i>Journal of Experimental Medicine</i> , <b>2003</b> , 198, 851-62	16.6	869
435	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1396-1407	59.2	780
434	Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2190-6	2.2	759
433	Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5027-33	2.2	759

432	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , <b>2003</b> , 3, 185-97	24.3	751
431	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 13520-5	11.5	746
430	Molecular diagnosis of Burkitt's lymphoma. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 2431-42	59.2	700
429	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3452-9	2.2	669
428	ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , <b>2008</b> , 111, 5496-504	2.2	664
427	Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. <i>Science</i> , <b>2008</b> , 319, 1676-9	33.3	660
426	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , <b>2012</b> , 490, 116-20	50.4	600
425	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>Blood</i> , <b>2014</b> , 123, 837-42	2.2	517
424	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. <i>Blood</i> , <b>2009</b> , 114, 3533-7	2.2	484
423	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. <i>Nature</i> , <b>2011</b> , 471, 377-81	50.4	467
422	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. <i>Blood</i> , <b>2009</b> , 114, 2273-9	2.2	439
421	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , <b>2014</b> , 123, 1214-7	2.2	404
420	Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases. <i>Blood</i> , <b>1997</b> , 89, 2067-2078	2.2	402
419	Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 607-14	2.2	389
418	Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). <i>Blood</i> , <b>2005</b> , 106, 2169-74	2.2	386
417	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 331-344	59.2	378
416	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1111-1122	21.7	347
415	De novo transcriptome assembly with ABySS. <i>Bioinformatics</i> , <b>2009</b> , 25, 2872-7	7.2	326

414	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , <b>2005</b> , 106, 3183-90	2.2	304
413	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , <b>2014</b> , 123, 2915-23	2.2	299
412	Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5165-9	2.2	291
411	Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. <i>Blood</i> , <b>2013</b> , 122, 1256-65	2.2	289
410	Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1812-26	2.2	283
409	ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 399-408	59.2	272
408	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. <i>Blood</i> , <b>2012</b> , 119, 1963-71	2.2	264
407	Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1970-6	2.2	260
406	Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4634-42	2.2	256
405	Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. <i>Blood</i> , <b>2011</b> , 118, 148-55	2.2	254
404	BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 961-8	2.2	238
403	Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1562-6	2.2	238
402	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2848-56	2.2	236
401	Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 35-40	2.2	235
400	BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. <i>American Journal of Pathology</i> , <b>2004</b> , 165, 159-66	5.8	232
399	Cooperative epigenetic modulation by cancer amplicon genes. <i>Cancer Cell</i> , <b>2010</b> , 18, 590-605	24.3	230
398	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. <i>Lancet Oncology</i> , <b>2013</b> , 14, 1348-56	21.7	212
397	Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 684-91	2.2	204

396	Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 897-906	2.2	201
395	CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3150-6	2.2	201
394	State-of-the-art therapeutics: Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6400-8	2.2	189
393	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , <b>2007</b> , 109, 4599-606	2.2	183
392	Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , <b>2015</b> , 125, 1236-43	2.2	176
391	Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2233-9	2.2	167
390	Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1452-7	2.2	163
389	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. <i>Blood</i> , <b>2012</b> , 120, 3280-7	2.2	159
388	Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 1558-67	2.2	158
387	Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 692-700	2.2	145
386	The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. <i>Blood</i> , <b>2010</b> , 115, 289-95	2.2	145
385	LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 447-54	2.2	143
384	Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. <i>Nature Genetics</i> , <b>2014</b> , 46, 329-35	36.3	141
383	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 190-201	2.2	137
382	Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. <i>Annals of Internal Medicine</i> , <b>1987</b> , 107, 25-30	8	137
381	Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 793-9	2.2	135
380	Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. <i>Cancer Research</i> , <b>2010</b> , 70, 9166-74	10.1	133
379	BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7785-95	12.9	132

378	International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3383-8	2.2	127
377	Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). <i>Genes Chromosomes and Cancer</i> , <b>2001</b> , 30, 375-82	5	127
376	Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 1065-72	12.9	127
375	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. <i>Cancer Discovery</i> , <b>2019</b> , 9, 546-563	24.4	123
374	Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. <i>Blood</i> , <b>2010</b> , 116, 418-27	2.2	123
373	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. <i>Blood</i> , <b>2017</b> , 130, 2709-2717	2.2	121
372	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , <b>2008</b> , 112, 3425-33	2.2	121
371	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , <b>2016</b> , 128, 1112-20	2.2	119
370	Prognostic factors in follicular lymphoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2902-13	2.2	117
369	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002197	11.6	110
368	High-grade B-cell lymphoma with and and/or rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , <b>2018</b> , 131, 2060-2064	2.2	107
367	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107, djv279	9.7	107
366	Organochlorines and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , <b>2007</b> , 121, 2767-75	7.5	107
365	Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. <i>Blood</i> , <b>2009</b> , 113, 3773-80	2.2	106
364	Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5170-4	2.2	105
363	Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. <i>Genes Chromosomes and Cancer</i> , <b>2004</b> , 39, 195-204	5	105
362	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. <i>Blood</i> , <b>2016</b> , 127, 2182-8	2.2	105
361	Recurrent targets of aberrant somatic hypermutation in lymphoma. <i>Oncotarget</i> , <b>2012</b> , 3, 1308-19	3.3	101

360	Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. <i>Cancer Discovery</i> , <b>2014</b> , 4, 480-93	24.4	100
359	Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. <i>Blood</i> , <b>2013</b> , 121, 3666-74	2.2	100
358	Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. <i>Blood</i> , <b>2012</b> , 120, 3530-40	2.2	100
357	High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. <i>Blood</i> , <b>2005</b> , 106, 1473-8	2.2	100
356	Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. <i>Blood</i> , <b>2009</b> , 113, 137-48	2.2	99
355	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. <i>Blood</i> , <b>2013</b> , 121, 3161-4	2.2	98
354	Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. <i>British Journal of Haematology</i> , <b>2003</b> , 120, 424-33	4.5	95
353	Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. <i>Lancet, The</i> , <b>1999</b> , 354, 1698-9	4.0	91
352	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , <b>2014</b> , 123, 1681-90	2.2	87
351	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , <b>2013</b> , 161, 76-86	4.5	86
350	Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. <i>Blood</i> , <b>2007</b> , 109, 4171-3	2.2	86
349	Genetic profiling of and in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. <i>Blood</i> , <b>2017</b> , 129, 2760-2770	2.2	82
348	Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1164-71	2.2	80
347	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Blood</i> , <b>2008</b> , 111, 5509-14	2.2	80
346	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , <b>2011</b> , 96, 996-1001	6.6	75
345	Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. <i>Cancer</i> , <b>2010</b> , 116, 3797-806	6.4	74
344	The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3428-35	12.9	73
343	Mantle cell lymphoma in the ocular adnexal region. <i>Ophthalmology</i> , <b>2005</b> , 112, 114-9	7.3	72

342	Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2005</b> , 131, 223-30	4.5	72
341	Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. <i>Genome Biology</i> , <b>2015</b> , 16, 18	18.3	71
340	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , <b>2016</b> , 7, 10933	17.4	70
339	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1668-1677	2.2	67
338	Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 257-266	21.7	67
337	Primary adrenal lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2003</b> , 4, 154-60		66
336	Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. <i>Nature Communications</i> , <b>2018</b> , 9, 4001	17.4	64
335	Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. <i>Blood</i> , <b>2014</b> , 123, 3567-73	2.2	63
334	Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. <i>Blood</i> , <b>2011</b> , 118, 4585-90	2.2	62
333	Cell of origin of transformed follicular lymphoma. <i>Blood</i> , <b>2015</b> , 126, 2118-27	2.2	60
332	Prognostic Significance of Bax Protein Expression in Diffuse Aggressive Non-Hodgkin's Lymphoma. <i>Blood</i> , <b>1997</b> , 90, 3173-3178	2.2	60
331	The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 519-28	1.9	60
330	Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1797-803	2.2	59
329	MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. <i>Annals of Oncology</i> , <b>1991</b> , 2 Suppl 1, 17-23	10.3	59
328	CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 1102-9	1.9	58
327	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , <b>2018</b> , 132, 413-422	2.2	58
326	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , <b>2020</b> , 135, 735-742	2.2	54
325	Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. <i>Haematologica</i> , <b>2011</b> , 96, 1002-7	6.6	53



324	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. <i>Haematologica</i> , <b>2010</b> , 95, 96-101	6.6	53
323	High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. <i>Clinical Lymphoma</i> , <b>2007</b> , 8, 788-793	2.2	52
322	Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 1041-6	7.1	50
321	TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. <i>Blood</i> , <b>2012</b> , 119, 4949-52	5.2	50
320	Reduced telomere length variation in healthy oldest old. <i>Mechanisms of Ageing and Development</i> , <b>2008</b> , 129, 638-41	5.6	49
319	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , <b>2012</b> , 120, 2290-6	2.2	48
318	Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. <i>British Journal of Haematology</i> , <b>2015</b> , 169, 520-7	4.5	47
317	Cytogenetic analysis in mantle cell lymphoma: a review of 214 cases. <i>Leukemia and Lymphoma</i> , <b>2002</b> , 43, 783-91	1.9	46
316	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 1322-30	6.7	45
315	Bone marrow involvement in T-cell-rich B-cell lymphoma. <i>American Journal of Clinical Pathology</i> , <b>1997</b> , 108, 570-8	1.9	45
314	Hodgkin's lymphoma in adolescents. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2520-6	2.2	44
313	Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. <i>Blood</i> , <b>2019</b> , 134, 761-764	2.2	43
312	Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 203-214	5.1	42
311	Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 719-25	4	42
310	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. <i>Blood</i> , <b>2019</b> , 134, 802-813	2.2	41
309	CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. <i>Haematologica</i> , <b>2009</b> , 94, 423-7	6.6	41
308	Prognostic significance of secondary cytogenetic alterations in follicular lymphomas. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 1038-48	5	41
307	Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , <b>2004</b> , 127, 311-21	4.5	41

306	Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 210-221	4.5	40
305	Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 34-41	1.9	40
304	High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. <i>Genes Chromosomes and Cancer</i> , <b>2010</b> , 49, 669-81	5	40
303	Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 1721-7	1.9	40
302	The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. <i>Cancer</i> , <b>2005</b> , 103, 1008-17	6.4	40
301	Hodgkin lymphoma. <i>Nature Reviews Disease Primers</i> , <b>2020</b> , 6, 61	51.1	39
300	Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2493-500	2.2	39
299	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , <b>2018</b> , 132, 2401-2405	2.2	39
298	Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. <i>Cancer</i> , <b>2012</b> , 118, 4156-65	6.4	38
297	Hand-assisted laparoscopic splenectomy versus open splenectomy for massive splenomegaly: 20-year experience at a Canadian centre. <i>Canadian Journal of Surgery</i> , <b>2011</b> , 54, 189-93	2	38
296	HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 542-6	1.9	38
295	High-resolution architecture and partner genes of rearrangements in lymphoma with DLBCL morphology. <i>Blood Advances</i> , <b>2018</b> , 2, 2755-2765	7.8	38
294	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , <b>2018</b> , 93, 57-68	7.5	37
293	Rituximab with high-dose methotrexate in primary central nervous system lymphoma. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 1149-54	7.1	37
292	Clinical manifestations and natural history of Hodgkin's lymphoma. <i>Cancer Journal (Sudbury, Mass.)</i> , <b>2009</b> , 15, 124-8	2.2	37
291	GBV-C/hepatitis G virus infection and non-Hodgkin lymphoma: a case control study. <i>International Journal of Cancer</i> , <b>2010</b> , 126, 2885-92	7.5	37
290	Comparison of American Joint Committee on Cancer TNM-based staging system (7th edition) and Ann Arbor classification for predicting outcome in ocular adnexal lymphoma. <i>Orbit</i> , <b>2014</b> , 33, 23-8	1.5	36
289	Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 1658-67	1.9	36

288	Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , <b>2010</b> , 21, 11-22	2.8	36
287	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. <i>European Journal of Cancer</i> , <b>2017</b> , 75, 195-203	7.5	35
286	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4019-4026	2.2	35
285	Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma. <i>Blood</i> , <b>2015</b> , 125, 1693-702	2.2	34
284	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , <b>2018</b> , 124, 136-144	6.4	34
283	Hodgkin lymphoma in pregnancy. <i>Current Hematologic Malignancy Reports</i> , <b>2013</b> , 8, 211-7	4.4	34
282	Vascularization predicts overall survival and risk of transformation in follicular lymphoma. <i>Haematologica</i> , <b>2010</b> , 95, 2157-60	6.6	34
281	Genetic variation in healthy oldest-old. <i>PLoS ONE</i> , <b>2009</b> , 4, e6641	3.7	33
280	Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. <i>Leukemia and Lymphoma</i> , <b>2002</b> , 43, 1395-402	1.9	33
279	Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 341-8	2	32
278	Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma. <i>American Journal of Clinical Pathology</i> , <b>2012</b> , 137, 75-85	1.9	32
277	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , <b>2007</b> , 46, 1090-7	5	32
276	Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2007</b> , 16, 1098-106	4	32
275	Treatment and outcomes of primary breast lymphoma. <i>Clinical Breast Cancer</i> , <b>2012</b> , 12, 412-9	3	31
274	Anaplastic large cell lymphoma: a clinicopathologic analysis. <i>Hematological Oncology</i> , <b>1999</b> , 17, 137-48	1.3	31
273	Primary, unilateral ocular adnexal lymphoma: disease progression and long-term survival. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , <b>2011</b> , 27, 405-9	1.4	30
272	Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. <i>British Journal of Haematology</i> , <b>2003</b> , 122, 745-59	4.5	30
271	Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia. <i>American Journal of Hematology</i> , <b>1992</b> , 41, 13-8	7.1	30

270	Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3722-3733	2.2	29
269	Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. <i>Cancer</i> , <b>2015</b> , 121, 423-31	6.4	28
268	Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. <i>Blood</i> , <b>2012</b> , 119, 1988-91	2.2	28
267	Diffuse malignant lymphoma with cerebriform nuclei: A B-cell lymphoma studied with monoclonal antibodies. <i>American Journal of Clinical Pathology</i> , <b>1985</b> , 83, 753-9	1.9	28
266	Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , <b>2017</b> , 130, 1375-1377	2.2	27
265	Characterization of the recurrent translocation t(1;1)(p36.3;q21.1-2) in non-Hodgkin lymphoma by multicolor banding and fluorescence in situ hybridization analysis. <i>Genes Chromosomes and Cancer</i> , <b>2003</b> , 36, 375-81	5	27
264	Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , <b>2019</b> , 186, e28-e31	4.5	25
263	Hodgkin's lymphoma--the great teacher. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 264-5	59.2	25
262	Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. <i>BMC Medical Genetics</i> , <b>2009</b> , 10, 117	2.1	25
261	R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.. <i>Blood</i> , <b>2009</b> , 114, 408-408	2.2	25
260	Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 324-332	1.9	24
259	Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 283-283	2.2	24
258	Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma. <i>Blood</i> , <b>2014</b> , 124, 394-394	2.2	24
257	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	22
256	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 577-588	50.5	22
255	Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 174-185	4.5	22
254	Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 97, 35-41	4	22
253	Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. <i>British Journal of Haematology</i> , <b>2006</b> , 133, 634-7	4.5	22

252	Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21. <i>Genes Chromosomes and Cancer</i> , <b>2004</b> , 40, 60-5	5	22
251	Clinical significance of the t(14;18) and BCL2 overexpression in follicular large cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 36, 513-23	1.9	22
250	The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era. <i>Blood</i> , <b>2012</b> , 120, 303-303	2.2	22
249	Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 630-3	7.5	21
248	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. <i>Oncotmunology</i> , <b>2017</b> , 6, e1321184	7.2	20
247	Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 77-82	1.9	20
246	Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 24-33	1.9	20
245	Challenging problems: coincident pregnancy, HIV infection, and older age. <i>Hematology American Society of Hematology Education Program</i> , <b>2008</b> , 334-9	3.1	20
244	The evolving role of etoposide in the management of lymphomas and Hodgkin's disease. <i>Cancer</i> , <b>1991</b> , 67, 271-80	6.4	20
243	Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , <b>2013</b> , 122, 1809-1809	2.2	20
242	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology,the</i> , <b>2021</b> , 8, e410-e421	14.6	20
241	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1718-1726	12.9	20
240	Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). <i>BMC Health Services Research</i> , <b>2013</b> , 13, 454	2.9	19
239	Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia. <i>Oncologist</i> , <b>2014</b> , 19, 283-90	5.7	19
238	Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. <i>Value in Health</i> , <b>2010</b> , 13, 703-11	3.3	19
237	Uncovering novel inter- and intrachromosomal chromosome 1 aberrations in follicular lymphomas by using an innovative multicolor banding technique. <i>Genes Chromosomes and Cancer</i> , <b>2002</b> , 34, 201-10	5	19
236	Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). <i>Blood</i> , <b>2014</b> , 124, 392-392	2.2	19
235	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , <b>2019</b> , 3, 2013-2021	7.8	19

234	Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , <b>2021</b> , 137, 929-938	2.2	19
233	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. <i>Blood</i> , <b>2018</b> , 131, 226-235	2.2	19
232	An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. <i>Blood</i> , <b>2015</b> , 125, 959-66	2.2	18
231	Positron emission tomography in the management of Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , <b>2011</b> , 2011, 317-22	3.1	18
230	Genetic variation in cell death genes and risk of non-Hodgkin lymphoma. <i>PLoS ONE</i> , <b>2012</b> , 7, e31560	3.7	18
229	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 876-883	4.5	18
228	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2226-36	12.9	17
227	Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 508-510	4.5	17
226	Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation. <i>Blood</i> , <b>2015</b> , 126, 579-579	2.2	16
225	Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 442-447	4.5	15
224	Elevated circulating t(14;18) translocation levels prior to diagnosis of follicular lymphoma. <i>Blood</i> , <b>2010</b> , 116, 6146-7	2.2	15
223	Cure of Ommaya reservoir associated Staphylococcus epidermidis ventriculitis with a simple regimen of vancomycin and rifampin without reservoir removal. <i>Medical and Pediatric Oncology</i> , <b>1982</b> , 10, 549-52		15
222	Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma. <i>Blood</i> , <b>1999</b> , 93, 3913-3921	2.2	15
221	Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 234-240	4.5	14
220	Treatment considerations in the elderly patient with lymphoma. <i>Hematology/Oncology Clinics of North America</i> , <b>1997</b> , 11, 949-61	3.1	14
219	Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 513-20	1.9	14
218	Hodgkin's lymphoma: the hazards of success. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 3388-90	2.2	14
217	Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma. <i>Blood</i> , <b>2013</b> , 122, 4382-4382	2.2	14

216	Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. <i>Blood Advances</i> , <b>2019</b> , 3, 3953-3961	7.8	13
215	A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 59-74	2	12
214	Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1813-8	4.7	12
213	Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma.. <i>Blood</i> , <b>2007</b> , 110, 790-790	2.2	12
212	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 717-20	1.9	11
211	Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 276-282	1.9	11
210	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 2852-63	7.5	11
209	Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 961-961	2.2	11
208	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 894-9	7.1	11
207	Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 757-760	4.5	10
206	Non-Hodgkin lymphoma: the clinician's perspective--a view from the receiving end. <i>Modern Pathology</i> , <b>2013</b> , 26 Suppl 1, S111-8	9.8	10
205	B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma. <i>American Journal of Clinical Pathology</i> , <b>2012</b> , 137, 805-14	1.9	10
204	Alemtuzumab in clinical practice: a British Columbia experience. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 218-26		10
203	Cytogenetic findings in reactive lymphoid hyperplasia: significance of non-clonal t(3;14) and t(3;22). <i>American Journal of Hematology</i> , <b>2002</b> , 70, 133-8	7.1	10
202	A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , <b>2002</b> , 43, 975-82	1.9	10
201	Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. <i>Blood</i> , <b>2011</b> , 118, 443-443	2.2	10
200	Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma: Long Term Outcomes. <i>Blood</i> , <b>2014</b> , 124, 292-292	2.2	10
199	Non-Hodgkin lymphoma risk and variants in genes controlling lymphocyte development. <i>PLoS ONE</i> , <b>2013</b> , 8, e75170	3.7	10

198	Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. <i>Blood</i> , <b>2020</b> , 136, 1006-1010	2.2	9
197	Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0180261	3.7	9
196	Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1560-1561	59.2	9
195	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. <i>Haematologica</i> , <b>2018</b> , 103, e590-e593	6.6	9
194	Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , <b>2006</b> , 108, 809-809	2.2	9
193	Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. <i>Haematologica</i> , <b>2016</b> , 101, e411-e414	6.6	9
192	The Super-Seniors Study: Phenotypic characterization of a healthy 85+ population. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197578	3.7	8
191	Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 782-790	4.5	8
190	Cost-effectiveness of rituximab in follicular lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2012</b> , 12, 569-77	2.2	8
189	A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , <b>2007</b> , 121, 1967-75	7.5	8
188	Controversies and Future Directions in the Therapy of Lymphoma. <i>Leukemia and Lymphoma</i> , <b>1998</b> , 30, 1-2	1.9	8
187	Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1987</b> , 10, 355-9	2.7	8
186	Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 4144-4144	2.2	8
185	Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma. <i>Blood</i> , <b>1997</b> , 90, 244-251	2.2	8
184	Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 540-549	4.5	8
183	Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2020</b> , 97, 620-629	4.6	8
182	Hodgkin lymphoma: outsmarting HRS cells. <i>Blood</i> , <b>2020</b> , 136, 2362-2364	2.2	8
181	Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1356-1363	1.9	7



180	Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 872-9	1.9	7
179	New strategies for the treatment of early stages of Hodgkin's lymphoma. <i>Hematology/Oncology Clinics of North America</i> , <b>2007</b> , 21, 871-80	3.1	7
178	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. <i>Blood</i> , <b>2018</b> , 132, 1618-1618	2.2	7
177	Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization.. <i>Blood</i> , <b>2004</b> , 104, 1407-1407	2.2	7
176	Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone.. <i>Blood</i> , <b>2007</b> , 110, 787-787	2.2	7
175	Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 4459-4459	2.2	7
174	Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 798-798	2.2	7
173	The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience. <i>Blood</i> , <b>2015</b> , 126, 586-586	2.2	7
172	Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , <b>2019</b> , 186, e24-e27	4.5	6
171	Lifetime physical activity and the risk of non-Hodgkin lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 873-7	4	6
170	Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 711-714	1.9	6
169	Gene Expression Signatures Predict Overall Survival in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.. <i>Blood</i> , <b>2007</b> , 110, 348-348	2.2	6
168	Mutations In MLL2 and MEF2B Genes In Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 473-473	2.2	6
167	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. <i>Blood</i> , <b>2012</b> , 120, 3701-3701	2.2	6
166	Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 2736-2736	2.2	6
165	A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy. <i>Blood</i> , <b>2015</b> , 126, 333-333	2.2	6
164	Hodgkin lymphoma in the elderly, pregnant, and HIV-infected. <i>Seminars in Hematology</i> , <b>2016</b> , 53, 203-8	4	6
163	High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 481-484	4.4	6

162	Nonrandom occurrence of lymphoid cancer types in 140 families. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1-10	1.9	5
161	Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 941-8	4.7	5
160	Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 470, 113-117	5.1	5
159	The cured lymphoma patient: guidelines for long-term follow-up. <i>Postgraduate Medicine</i> , <b>1982</b> , 72, 53-7, 59	3.7	5
158	Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2873-2873	2.2	5
157	Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis.. <i>Blood</i> , <b>2006</b> , 108, 3051-3051	2.2	5
156	Outcome in Unselected Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Following R-CHOP When Stem Cell Transplantation Is Not Feasible. <i>Blood</i> , <b>2014</b> , 124, 3069-3069	2.2	5
155	Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7539-7539	2.3	5
154	The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. <i>Blood</i> , <b>2021</b> , 137, 2196-2208	2.2	5
153	Genetic polymorphism at as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , <b>2017</b> , 102, e199-e202	6.6	4
152	Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 382-389	2	4
151	Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	4
150	I. Hodgkin lymphoma: special challenges and solutions. <i>Hematological Oncology</i> , <b>2015</b> , 33 Suppl 1, 21-4	1.3	4
149	Clinicopathological analysis of follicular lymphoma with a polyploid karyotype. <i>Leukemia and Lymphoma</i> , <b>1998</b> , 28, 383-9	1.9	4
148	Identification of risk factors in patients treated for first relapse of Hodgkin's disease. <i>Leukemia and Lymphoma</i> , <b>1994</b> , 15, 189-200	1.9	4
147	Who Actually Detects Relapse in Hodgkin Lymphoma: Patient or Physician?.. <i>Blood</i> , <b>2004</b> , 104, 3124-3124	4.2	4
146	Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study.. <i>Blood</i> , <b>2008</b> , 112, 975-975	2.2	4
145	Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment. <i>Blood</i> , <b>2010</b> , 116, 1751-1751	2.2	4

144	Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2014</b> , 124, 703-703	2.2	4
143	Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 122-127	4.5	4
142	Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. <i>Hematological Oncology</i> , <b>2019</b> , 37, 35-38	1.3	4
141	Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma. <i>Blood</i> , <b>2021</b> , 137, 1256-1259	2.2	4
140	Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 560-567	4.5	4
139	Treatment of diffuse large B-cell lymphoma: a risk-based approach. <i>Clinical Lymphoma and Myeloma</i> , <b>2006</b> , 7 Suppl 1, S14-9		3
138	Mechanisms of Bcl-2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , <b>2004</b> , 104, 26-26	2.2	3
137	Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).. <i>Blood</i> , <b>2005</b> , 106, 817-817	2.2	3
136	The Architectural Pattern of FOXP3+ T Cells Predicts Risk of Transformation in Patients with Follicular Lymphoma (FL).. <i>Blood</i> , <b>2007</b> , 110, 358-358	2.2	3
135	FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP. <i>Blood</i> , <b>2010</b> , 116, 854-854	2.2	3
134	Whole Transcriptome Sequencing Reveals Recurrent NOTCH1 Mutations in Mantle Cell Lymphoma. <i>Blood</i> , <b>2011</b> , 118, 436-436	2.2	3
133	The Outcome of Advanced Stage Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Compared to Classical Hodgkin's Lymphoma (CHL): A Matched Pair Analysis. <i>Blood</i> , <b>2012</b> , 120, 1531-1531	2.2	3
132	Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. <i>Blood</i> , <b>2012</b> , 120, 2745-2745	2.2	3
131	Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 3689-3689	2.2	3
130	A Phase 1 -2 Study of Brentuximab Vedotin (Bv) and Bendamustine (B) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL). <i>Blood</i> , <b>2014</b> , 124, 3084-3084	2.2	3
129	Outcome of Observation As Initial Strategy in Patients with Mantle Cell Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 2699-2699	2.2	3
128	Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS8613-TPS8613	2.2	3
127	Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. <i>Blood Advances</i> , <b>2021</b> , 5, 1483-1489	7.8	3

126	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. <i>Hematological Oncology</i> , <b>2021</b> , 39, 185-195	1.3	3
125	Advanced-Stage Hodgkin Lymphoma: New Approaches Based on Novel Therapeutic Agents or Treatment Intensification. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2018</b> , 24, 230-236	2.2	3
124	Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting. <i>Clinical Trials</i> , <b>2016</b> , 13, 545-54	2.2	2
123	Identification of a novel non-immunoglobulin/MYC translocation t(8;12)(q24;p12) involving the LRMP gene in a primary B-cell lymphoma. A case report. <i>Leukemia Research</i> , <b>2012</b> , 36, e22-4	2.7	2
122	Treatment of NLPHL. <i>Blood</i> , <b>2013</b> , 122, 4288-9	2.2	2
121	Is there a role for MACOP-B in the treatment of diffuse large cell lymphoma?. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 10 Suppl, 85-9	1.9	2
120	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 1560-1560	2.2	2
119	FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan.. <i>Blood</i> , <b>2007</b> , 110, 213-213	2.2	2
118	Allogeneic Stem Cell Transplantation as Treatment for Relapsed and High-Risk Peripheral T-Cell Lymphoma.. <i>Blood</i> , <b>2007</b> , 110, 3040-3040	2.2	2
117	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.. <i>Blood</i> , <b>2007</b> , 110, 52-52	2.2	2
116	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. <i>Blood</i> , <b>2007</b> , 110, 692-692	2.2	2
115	Follicular Non-Hodgkin Lymphoma Grade 3a and 3b Subtypes Exhibit Similar Clinical Behaviour and Treatment Outcome. <i>Blood</i> , <b>2008</b> , 112, 3777-3777	2.2	2
114	Deletion in Chromosome 17p12 and Gains in Chromosome 9q33.3 by Array Comparative Hybridization Are Associated with R-CHOP Treatment Failure in Patients with Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 477-477	2.2	2
113	HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy.. <i>Blood</i> , <b>2009</b> , 114, 133-133	2.2	2
112	Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials. <i>Blood</i> , <b>2010</b> , 116, 417-417	2.2	2
111	Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6. <i>Blood</i> , <b>2011</b> , 118, 590-590	2.2	2
110	Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era. <i>Blood</i> , <b>2011</b> , 118, 780-780	2.2	2
109	Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors. <i>Blood</i> , <b>2011</b> , 118, 96-96	2.2	2

108	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1874-1874	2.2	2
107	EFS24 as a predictor of outcome in a population-based cohort of patients with DLBCL in British Columbia (BC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7569-7569	2.2	2
106	New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 626-636 <sup>1</sup>	7.1	2
105	Anaplastic large cell lymphoma: a clinicopathologic analysis <b>1999</b> , 17, 137		2
104	Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2114-22	1.9	1
103	Birth Order, Sibship Size, Childhood Environment and Immune-Related Disorders, and Risk of Lymphoma in Lymphoid Cancer Families. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 1168-1178 <sup>1</sup>	4.1	1
102	Is the lymphoma better? Not easy to determine. <i>Blood</i> , <b>2016</b> , 128, 2481-2482	2.2	1
101	Immune Checkpoint Inhibition: A New Era in Lymphoma Treatment. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 109-10	3.1	1
100	Chemotherapy only in early stage Hodgkin lymphoma: more relapses but the same survival--what to do?. <i>Current Hematologic Malignancy Reports</i> , <b>2014</b> , 9, 217-21	4.4	1
99	Sex- and subtype-specific analysis of H2AFX polymorphisms in non-Hodgkin lymphoma. <i>PLoS ONE</i> , <b>2013</b> , 8, e74619	3.7	1
98	Clinical impact of pathology reviews of outside material: a patient-focused approach. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4212-3	2.2	1
97	The case for chemotherapy alone for limited-stage Hodgkin's lymphoma. <i>Oncologist</i> , <b>2012</b> , 17, 1011-3	5.7	1
96	Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray. <i>Blood</i> , <b>2018</b> , 132, 348-348	2.2	1
95	The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL. <i>Blood</i> , <b>2018</b> , 132, 921-921	2.2	1
94	Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience. <i>Blood</i> , <b>2018</b> , 132, 2907-2907	2.2	1
93	Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach. <i>Blood</i> , <b>2019</b> , 134, 2845-2845	2.2	1
92	Transformed Lymphoma: Incidence and Long-Term Outcome.. <i>Blood</i> , <b>2004</b> , 104, 3253-3253	2.2	1
91	Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphoblastic Lymphoma (T-LBL) : An Intention to Treat Analysis.. <i>Blood</i> , <b>2004</b> , 104, 900-900	2.2	1

90	Survival of Limited Stage Peripheral T-Cell Lymphoma Is Similar To Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , <b>2005</b> , 106, 2817-2817	2.2	1
89	Insights into Disease Evolution of Transformed Follicular Lymphoma Derived from Cytogenetics.. <i>Blood</i> , <b>2005</b> , 106, 604-604	2.2	1
88	Clinicopathologic Subtypes of Mantle Cell Lymphoma (MCL) Show Distinct Patterns of Genetic Copy Number Alteration.. <i>Blood</i> , <b>2006</b> , 108, 2049-2049	2.2	1
87	Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT.. <i>Blood</i> , <b>2008</b> , 112, 2173-2173	2.2	1
86	The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.. <i>Blood</i> , <b>2009</b> , 114, 2923-2923	2.2	1
85	Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).. <i>Blood</i> , <b>2009</b> , 114, 3944-3944	2.2	1
84	Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL). <i>Blood</i> , <b>2010</b> , 116, 113-113	2.2	1
83	Incorporation of ABVD Increases Cure Rates of Patients with Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL). <i>Blood</i> , <b>2010</b> , 116, 3887-3887	2.2	1
82	Identification of Genes Frequently Mutated In FL and DLBCL with Transcriptome, Genome and Exome Sequencing. <i>Blood</i> , <b>2010</b> , 116, 804-804	2.2	1
81	A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma A Correlative Study From the E2496 Intergroup Trial. <i>Blood</i> , <b>2011</b> , 118, 430-430	2.2	1
80	Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. <i>Blood</i> , <b>2014</b> , 124, 3016-3016	2.2	1
79	FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance. <i>Blood</i> , <b>2014</b> , 124, 3018-3018	2.2	1
78	Rituximab with High Dose Methotrexate in the Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2014</b> , 124, 3090-3090	2.2	1
77	ABVD Chemotherapy Results in Excellent Outcomes with Reduced Radiation Therapy Rates in Children, Adolescents and Young Adults with Hodgkin Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 2695-2695	2.2	1
76	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , <b>2015</b> , 126, 3905-3905	2.2	1
75	A Novel Prognostic Model Based on Tumor Microenvironment Biology in Relapse Biopsies Predicts Post-Autologous Stem Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1093-1093	2.2	1
74	Second Malignancies in Patients With Hairy Cell Leukemia in British Columbia: A 20-Year Experience. <i>Blood</i> , <b>1998</b> , 92, 1160-1164	2.2	1
73	Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7510-7510	2.2	1

72	Genome-wide discovery of somatic coding and regulatory variants in Diffuse Large B-cell Lymphoma		1
71	Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing		1
70	Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging. <i>Blood</i> , <b>2014</b> , 124, 1630-1630	2.2	1
69	Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 607-607	2.2	1
68	Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations.. <i>Blood</i> , <b>2009</b> , 114, 268-268	2.2	1
67	TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis.. <i>Blood</i> , <b>2009</b> , 114, 1919-1919	2.2	1
66	Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , <b>2013</b> , 122, 242-242	2.2	1
65	Hepatic dysfunction during and after lymphoma chemotherapy in patients with hepatitis C. <i>Journal of Clinical Gastroenterology</i> , <b>2006</b> , 40, 636-8	3	0
64	Lymphoma-Associated Macrophage (LAM) Content Is an Independent Predictor of Survival in Patients with Follicular Lymphoma (FL).. <i>Blood</i> , <b>2004</b> , 104, 3259-3259	2.2	0
63	Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.. <i>Blood</i> , <b>2006</b> , 108, 3662-3662	2.2	0
62	Outcome of elderly patients with classical Hodgkin lymphoma (HL) in British Columbia.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8031-8031	2.2	0
61	Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis. <i>Blood</i> , <b>2015</b> , 126, 2636-2636	2.2	0
60	Tattoos and Hematologic Malignancies in British Columbia, Canada. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 2093-2095	4	0
59	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. <i>Blood Advances</i> , <b>2021</b> , 5, 3647-3655	7.8	0
58	CRIS: complete reconstruction of immunoglobulin sequences from RNA-seq data. <i>Bioinformatics Advances</i> , <b>2021</b> , 1, vbab021		0
57	To treat or not to treat, that is the NLPHL question. <i>Blood</i> , <b>2019</b> , 133, 2113-2114	2.2	
56	Interview: Learning from lymphocytes: a career studying lymphoid cancer. <i>International Journal of Hematologic Oncology</i> , <b>2014</b> , 3, 15-17	1	
55	Reply to D.E. Roos. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1147-1147	2.2	

54	Insulin therapy in diabetic ketoacidosis. <i>Annals of Internal Medicine</i> , <b>1977</b> , 86, 109-11	8
53	Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada. <i>Blood</i> , <b>2020</b> , 136, 13-15	2.2
52	Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 18-19	2.2
51	Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC). <i>Blood</i> , <b>2020</b> , 136, 33-34	2.2
50	HLA-DR Protein Status Predicts Survival in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with the MACOP-B Chemotherapy Regimen.. <i>Blood</i> , <b>2004</b> , 104, 3273-3273	2.2
49	Acceptable Outcomes for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) for Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , <b>2004</b> , 104, 3325-3325	2.2
48	High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.. <i>Blood</i> , <b>2004</b> , 104, 697-697	2.2
47	Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group.. <i>Blood</i> , <b>2004</b> , 104, 1372-1372	2.2
46	Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.. <i>Blood</i> , <b>2006</b> , 108, 2739-2739	2.2
45	Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.. <i>Blood</i> , <b>2006</b> , 108, 3039-3039	2.2
44	Long Term Follow-Up Results for Patients with Hodgkin Lymphoma after First Remission of Longer Than Ten Years: A Population Based Study of 954 Patients from the British Columbia Cancer Agency.. <i>Blood</i> , <b>2006</b> , 108, 2269-2269	2.2
43	Correlation of DNA Copy Number, Gene Expression, Protein Expression and Clinical Outcome in a Group of Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with CHOP Plus Rituximab (CHOP-R).. <i>Blood</i> , <b>2006</b> , 108, 2027-2027	2.2
42	Both Discordant and Concordant Bone Marrow (BM) Involvement Predict for a Poorer Outcome Independent of the IPI in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP.. <i>Blood</i> , <b>2007</b> , 110, 1559-1559	2.2
41	CD20 Mutations at the Rituximab Binding Site Are Rare and Are Not a Significant Cause of R-CHOP Resistance in Patients with De Novo Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , <b>2007</b> , 110, 686-686	2.2
40	Vascularization Predicts Overall Survival (OS) & Risk of Transformation (RT) in Uniformly Treated Patients with Follicular Lymphoma (FL).. <i>Blood</i> , <b>2007</b> , 110, 184-184	2.2
39	Validation of a Simplified International Prognostic Score (IPS-3) in Patients with Advanced Stage Hodgkin Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2916-2916	2.2
38	The outcome of patients with "nodal" peripheral T-cell lymphomas in a complete response following standard chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8555-8555	2.2
37	Analysis of Relapse Biopsies in Classical Hodgkin Lymphoma Reveals Correlations with Outcome after Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2014</b> , 124, 136-136	2.2



36	Role of Bone Marrow Biopsy in the Staging of Diffuse Large B-Cell Lymphoma in the PET/CT Era. <i>Blood</i> , <b>2014</b> , 124, 2960-2960	2.2
35	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. <i>Blood</i> , <b>2014</b> , 124, 1667-1667	2.2
34	Primary Cutaneous Anaplastic Large Cell Lymphoma: The British Columbia Cancer Agency Experience. <i>Blood</i> , <b>2014</b> , 124, 3076-3076	2.2
33	Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , <b>2015</b> , 126, 3950-3950	2.2
32	Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 2919-2919	2.2
31	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 920-920	2.2
30	Outcome of Hodgkin Lymphoma after Progression Following Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2016</b> , 128, 2994-2994	2.2
29	Divergent Modes of Tumor Evolution Underlie Histological Transformation and Early Progression of Follicular Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1091-1091	2.2
28	Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia. <i>Blood</i> , <b>2016</b> , 128, 5852-5852	2.2
27	Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada. <i>Blood</i> , <b>2016</b> , 128, 1113-1113	2.2
26	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 475-475	2.2
25	Genetic Alterations Detected by High-Resolution Array Comparative Genomic Hybridization in Microdissected HRS Cells Correlate with Treatment Outcome in Classical Hodgkin Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 522-522	2.2
24	Impact of Comorbidity Index on Outcome with Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2008</b> , 112, 3305-3305	2.2
23	Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 520-520	2.2
22	Base-Pair Resolution of Somatic and Germline-Derived Genome Rearrangement Breakpoints in Follicular Lymphoma.. <i>Blood</i> , <b>2009</b> , 114, 439-439	2.2
21	Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (. <i>Blood</i> , <b>2009</b> , 114, 2872-2872	2.2
20	Fludarabine (F) and Rituximab (R) (FR) as Initial Therapy for Symptomatic Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): Population-Based Experience Matches Clinical Trials.. <i>Blood</i> , <b>2009</b> , 114, 2363-2363	2.2
19	The Management of Hodgkin Lymphoma During Pregnancy <b>2011</b> , 241-248	

- 18 Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. *Blood*, **2010**, 116, 2005-2005 2.2
- 17 The Prognosis of Limited Stage Peripheral T-Cell Lymphoma (PTCL): A Population-Based Analysis and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL). *Blood*, **2010**, 116, 4129-4129 2.2
- 16 Fludarabine and Rituximab (FR) Is a Safe and Effective Treatment Alternative for Relapsed or Refractory Hairy Cell Leukemia (HCL). *Blood*, **2010**, 116, 2454-2454 2.2
- 15 Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets. *Blood*, **2010**, 116, 632-632 2.2
- 14 Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance. *Blood*, **2010**, 116, 1803-1803 2.2
- 13 BCL2 Is Highly Mutated In Diffuse Large B-Cell Lymphoma. *Blood*, **2010**, 116, 4187-4187 2.2
- 12 CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome. *Blood*, **2011**, 118, 427-427 2.2
- 11 Chemoresistance Can Be Reliably Overcome with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT/ASCT) for Relapsed and Refractory Hodgkin's Lymphoma. *Blood*, **2011**, 118, 2022-2022 2.2
- 10 Population Survey of Mantle Cell Lymphoma (MCL) in British Columbia (BC) Is a Heterogeneous Disorder with Improved Outcomes in the Modern Era. *Blood*, **2012**, 120, 1602-1602 2.2
- 9 FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma. *Blood*, **2012**, 120, 1549-1549 2.2
- 8 Prognostic Factors in Patients with HIV-Associated Hodgkin Lymphoma: An Analysis of 199 Cases. *Blood*, **2012**, 120, 1528-1528 2.2
- 7 Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation. *Blood*, **2012**, 120, 295-295 2.2
- 6 Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival. *Blood*, **2013**, 122, 500-500 2.2
- 5 Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue [An L.L.M.P.P. Project]. *Blood*, **2013**, 122, 73-73 2.2
- 4 The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas. *Blood*, **2013**, 122, 1804-1804 2.2
- 3 Introduction From the Guest Editor: Hodgkin Lymphoma: Integrating New Therapies to Improve Outcomes. *Cancer Journal (Sudbury, Mass)*, **2018**, 24, 205 2.2
- 2 Letter comments on a published article in the New England Journal of Medicine. *European Journal of Cancer*, **2018**, 104, 250-251 7.5
- 1 Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review.. *Leukemia and Lymphoma*, **2022**, 1-4 1.9

